Keyphrases
Acute Kidney Injury
44%
Arterial Properties
100%
Arterial Stiffness
51%
Augmentation Index
27%
Body Composition
47%
Calcium Overload
42%
Cardiovascular Disease
29%
Cardiovascular Morbidity
48%
Cardiovascular Mortality
28%
Cardiovascular Risk
83%
Confidence Interval
52%
Coronary Artery Disease
31%
Coronary Risk Factors
26%
Daidzein
44%
Diabetes
30%
Diabetic Patients
26%
Differentiated Thyroid Carcinoma
65%
Endothelial Function
49%
Estrogen Receptor
35%
Flow-mediated Dilation
28%
Growth Inhibition
25%
Hormone Levels
32%
Human Thyroid
28%
Isoflavone Derivatives
63%
Israeli
28%
Long-term Mortality
42%
Metabolic Syndrome
42%
Myocardial Infarction Patients
52%
Neck Dissection
63%
Normal Thyroid
26%
O-carboxymethyl
44%
Older Adults
29%
Oral Calcium
42%
Papillary Thyroid Carcinoma
96%
Percutaneous Coronary Intervention
42%
Population-based Cohort Study
25%
Primary Hyperparathyroidism (pHPT)
25%
Pulse Wave Velocity
45%
Recurrence Pattern
42%
ST-elevation Myocardial Infarction (STEMI)
52%
Subclinical Hypothyroidism
44%
Therapeutic Levels
42%
Thyroid Cancer
85%
Thyroid Cancer Survivors
47%
Thyroid Carcinoma Cells
42%
Thyroid Hormones
35%
Thyroidectomy
26%
Total Thyroidectomy
44%
Vascular Parameters
31%
Vitamin D Receptor
26%
Medicine and Dentistry
1 Alkyl 2 Acetylglycerophosphocholine Esterase
21%
Acute Kidney Injury
36%
Aldosterone Release
21%
All Cause Mortality
21%
Arterial Stiffness
29%
Cardiovascular Risk
50%
Cardiovascular System
51%
Clinical Nutrition
21%
Cohort Analysis
42%
Daidzein
21%
Diabetes
32%
Diabetes Mellitus
27%
Diastolic Blood Pressure
25%
Differentiated Thyroid Cancer
63%
Dyslipidemia
31%
Endothelial Function
47%
Estrogen Receptor
21%
Evolocumab
21%
Hemoglobin A1c
21%
Hormone Determination
36%
Hyperglycemia
21%
Ischemic Heart Disease
37%
Isotopes of Calcium
42%
Low Density Lipoprotein Cholesterol
27%
Maturity Onset Diabetes of the Young
24%
Meta-Analysis
23%
Metabolic Syndrome
42%
Multiple Myeloma
21%
Myocardial Infarction
46%
Neck Dissection
63%
Papillary Thyroid Cancer
49%
Parathyroid Adenoma
21%
Percutaneous Coronary Intervention
42%
Primary Hyperparathyroidism
25%
Primary Percutaneous Coronary Intervention
23%
Pulse Wave Velocity
33%
Quality Adjusted Life Year
21%
Randomized Clinical Trial
21%
Recurrent Disease
56%
Renal Failure
21%
Resistance Training
21%
Resting Energy Expenditure
21%
Retrospective Cohort Study
24%
Self-Diagnosis
21%
Smouldering Myeloma
21%
Subclinical Hypothyroidism
42%
Substitution Therapy
21%
Thyroid Cancer
63%
Thyroidectomy
53%
Thyrotropin
35%
Pharmacology, Toxicology and Pharmaceutical Science
1 Alkyl 2 Acetylglycerophosphocholine Esterase
21%
Acute Kidney Failure
36%
Adverse Outcome
21%
Alcohol Liver Disease
10%
All Cause Mortality
42%
Antithyroid Agent
21%
Calcitriol
21%
Cardiovascular Disease
21%
Cardiovascular Risk
50%
Cohort Study
28%
Coronavirinae
21%
Daidzein
44%
Diabetes Mellitus
24%
Differentiated Thyroid Cancer
22%
Diseases
27%
Dyslipidemia
23%
Estrogen Receptor
34%
Ferritin
21%
Frailty
21%
Goiter
21%
Heart Infarction
48%
Hemoglobin A1c
21%
Hepatitis B Virus
10%
Hepatitis C Virus
10%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
25%
Hyperglycemia
21%
Hypothyroidism
10%
Ischemic Heart Disease
37%
Isoflavone
63%
Kidney Failure
21%
Liver Disease
10%
Low Density Lipoprotein Cholesterol
15%
Malignant Neoplasm
16%
Messenger RNA
32%
Nonalcoholic Fatty Liver
21%
Parathyroid Adenoma
21%
Primary Hyperparathyroidism
49%
Random Effects Model
21%
Randomized Clinical Trial
21%
Recurrent Disease
21%
Sorafenib
21%
ST Segment Elevation Myocardial Infarction
16%
Statin (Protein)
21%
Subclinical Hypothyroidism
42%
Synapsin I
16%
Thyroid Cancer
73%
Thyroid Carcinoma
54%
Thyroid Papillary Carcinoma
67%
Thyrotropin
33%
Vitamin D Receptor
26%